Evaxion Biotech A/S (EVAX)
NASDAQ: EVAX · IEX Real-Time Price · USD
3.720
-0.130 (-3.38%)
May 17, 2024, 3:59 PM EDT - Market closed
Evaxion Biotech Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Evaxion Biotech stock have an average target of 11, with a low estimate of 8.00 and a high estimate of 14. The average target predicts an increase of 195.70% from the current stock price of 3.72.
Analyst Consensus: Strong Buy
* Price targets were last updated on Apr 3, 2024.
Analyst Ratings
The average analyst rating for EVAX stock from 2 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 | May '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 2 | 2 | 2 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 1 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 3 | 3 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $14 | Strong Buy | Reiterates | $14 | +276.34% | Apr 3, 2024 |
| Ladenburg Thalmann | Ladenburg Thalmann | Hold → Strong Buy Upgrades $8 | Hold → Strong Buy | Upgrades | $8 | +115.05% | Apr 2, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $14 | Strong Buy | Reiterates | $14 | +276.34% | Mar 20, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $14 | Strong Buy | Initiates | $14 | +276.34% | Feb 12, 2024 |
| Ladenburg Thalmann | Ladenburg Thalmann | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Dec 21, 2023 |
Financial Forecast
Revenue This Year
4.93M
from 73.00K
Increased by 6,652.05%
Revenue Next Year
18.76M
from 4.93M
Increased by 280.54%
EPS This Year
-2.12
from -8.10
EPS Next Year
0.02
from -2.12
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 14.7M | 36.9M | 128.1M | 30.6M | 95.6M |
| Avg | 4.9M | 18.8M | 64.8M | 29.7M | 92.9M |
| Low | n/a | n/a | 4.9M | 28.5M | 89.2M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 20,037.0% | 649.1% | 582.8% | -52.8% | 221.8% |
| Avg | 6,652.1% | 280.5% | 245.2% | -54.1% | 212.6% |
| Low | - | - | -73.9% | -55.9% | 200.3% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -0.38 | 4.31 | 4.20 | - | 0.39 |
| Avg | -2.12 | 0.02 | 4.08 | - | 0.38 |
| Low | -3.72 | -3.99 | 3.92 | - | 0.36 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | 27,351.0% | - | - |
| Avg | - | - | 26,566.7% | - | - |
| Low | - | - | 25,520.9% | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.